A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jul 2018
At a glance
- Drugs Irinotecan (Primary) ; Capecitabine
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms ARISTOTLE
- 15 Jan 2018 Planned End Date changed from 25 Oct 2022 to 29 Dec 2023.
- 01 Jun 2016 Planned number of patients changed from 920 to 600.
- 24 Mar 2016 Accrual to date is 66% according to United Kingdom Clinical Research Network record.